Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer-Reference-Cited by-同舟云学术

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

Published:2010-05-17 Issue:5 Volume:1 Page:209-213
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Xu Lianhong¹,Liu Hongtao¹,Murray Bernard P.²,Callebaut Christian³,Lee Melody S.²,Hong Allen¹,Strickley Robert G.⁴,Tsai Luong K.³,Stray Kirsten M.³,Wang Yujin²,Rhodes Gerry R.²,Desai Manoj C.¹

Affiliation:

1. Department of Medicinal Chemistry

2. Drug Metabolism

3. Biology

4. Formulation

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml1000257

Reference31 articles.

1. Antiretroviral Treatment of Adult HIV Infection

2. Panel on Antiretroviral Guidelines for Adults and Adolescent, Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents; December 1, 2009; pp1−168and references therein. Available atContentFiles/AdultandAdolescentGL.pdf.

3. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy

4. Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis

5. Using Pharmacokinetics to Optimize Antiretroviral Drug-Drug Interactions in the Treatment of Human Immunodeficiency Virus Infection

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir;Archives of Biochemistry and Biophysics;2024-08

2. Quinoxaline clubbed thiazole: Molecular docking, synthesis and antimicrobial evaluation;Journal of the Indian Chemical Society;2024-07

3. Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors;European Journal of Medicinal Chemistry;2024-07

4. In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition;Drug Metabolism and Pharmacokinetics;2024-06

5. Increasing the bioavailability of oral esketamine by a single dose of cobicistat: A case study;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05-31